The Chengdu facility, which will be equipped with a 15,000L fermenter, is slated for Good Manufacturing Practice readiness for production by the end of the year.
The collaboration integrates testing, engineering, and regulatory expertise to improve coordination and reduce risk for complex drug-device combination products.
